Cardiac embolism accounts for an increasing proportion of ischemic strokes and might
multiply several-fold during the next decades. However, research points to several potential …

BACKGROUND: Warfarin is effective for stroke prevention in atrial fibrillation (AF), but
anticoagulation is underused in clinical care. The risk of venous thromboembolic disease …

The aim of this updated statement is to provide comprehensive and timely evidence-based
recommendations on the prevention of stroke among individuals who have not previously …

ESC Guidelines 2721 the outcome of disease may be favourably influenced by the thorough
application of clinical recommendations. Thus, the task of writing guidelines covers not only …

Background More accurate and reliable stroke risk prediction tools are needed to optimize
anticoagulation decision making in patients with atrial fibrillation (AF). We developed a new …

前言自2010 年中华医学会心电生理和起搏分会(China Society of Pacing and
Electrophysiology, CSPE) 制订并发表《 心房颤动: 目前的认识和治疗建议——2010》 以来 …

Background—Little is known regarding the adoption of direct thrombin inhibitors in clinical
practice. We examine trends in oral anticoagulation for the prevention of thromboembolism …

Background and Purpose—To estimate the cost-effectiveness of stroke prevention in
patients with nonvalvular atrial fibrillation by using novel oral anticoagulants apixaban 5 mg …

Background: Although warfarin has been extensively studied in clinical trials, little is known
about rates of hemorrhage attributable to its use in routine clinical practice. Our objective …

Background Dabigatran, rivaroxaban, and apixaban have been approved for use in patients
with atrial fibrillation based upon randomized trials demonstrating their comparable or …